MaxCyte, Inc. Block Listing Application (9212D)
May 02 2017 - 7:42AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 9212D
MaxCyte, Inc.
02 May 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Block Listing Application
MaxCyte (AIM: MXCT, MXCR) provides notification that an
application has been made to the London Stock Exchange for
admission to AIM for a block listing of 1,000,000 ordinary shares
of common stock of $0.01 each in the Company.
These shares, which will be identical in all respects with the
existing issued shares of the common stock in the Company, will not
be allotted immediately but rather will be allotted from time to
time as and when options are exercised under the MaxCyte Long Term
Incentive Plan.
It is expected that admission will become effective on or around
5 May 2017.
- ENDS -
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated
to driving the acceleration of the discovery, development,
manufacturing and commercialization of next-generation, cell-based
medicines. The Company provides its patented, high-performance cell
engineering platform to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery platform, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
platform allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering platform is
FDA-accredited, providing MaxCyte's customers and partners with an
established regulatory path to commercialize cell-based medicines.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSUGURWAUPMGPP
(END) Dow Jones Newswires
May 02, 2017 08:42 ET (12:42 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024